Format

Send to

Choose Destination
Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Author information

1
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. farbodshojaei@hotmail.com

Abstract

Angiogenesis is critical for growth of many tumor types and the development of anti-angiogenic agents opened a new era in cancer therapy. However, similar to other anti-cancer therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in cancer patients leading to disease recurrence. Recent studies in several experimental models suggest that both tumor and non-tumor (stromal) cell types may be involved in the reduced responsiveness to the treatments. The current review focuses on the role of stromal cells in tumor growth and in refractoriness to anti-VEGF treatment.

PMID:
18948057
DOI:
10.1016/j.drup.2008.09.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center